Hospital Universitario Puerta de Hierro-Majadahonda
Majadahonda (Madrid), Madrid, 28222, Spain
NCT Number: NCT02065024
Regular consumption of a beverage containing β-cryptoxanthin (b-Cx) and plant sterols (Ps) has been shown to exert a synergic effect in reducing cardiovascular risk and bone remodeling markers (formation and resorption). The present project aims to assess the influence of technological treatment and genetic variability on the bioavailability and the health effects of the added components (Ps, b-Cx), in particular to their potential role in prevalent disorders.In vitro and in vivo studies will be carried out to this effect. In vitro and in vivo studies (human intervention study) will be performed and cardiovascular, bone turnover and inflammation markers will be evaluated. Additionally, an in vitro colonic fermentation model and cell cultures will be used to explore anticarcinogenic effects and potential cytotoxicity.
Looking for future studies?
Notify Me45 year–65 year
Female
Interventional
Phase 1
Majadahonda (Madrid), Madrid, 28222, Spain
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 weeks of intervention
Time frame: 6 weeks
Time frame: 6 weks of intervention
Time frame: 6 weeks
Time frame: 6 weeks
Time frame: 6 weeks
Time frame: 6 weeks
Time frame: 6 weeks
Time frame: 6 weeks
Time frame: Baseline
Puerta de Hierro University Hospital
Other
Food Matrix and Genetic Variability as Determinants of the Bioavailability and Biological Effects of a B-cryptoxanthin and Phytosterols-enriched Beverage; In Vitro and in Vivo Evaluation
Acronym: foodmagenpol
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02342015
Bone Diseases, Bone Diseases, Metabolic
View Trial DetailsNCT00000466
Bone Diseases, Bone Diseases, Metabolic
View Trial DetailsNCT06359353
Bone Diseases, Bone Diseases, Metabolic
Seongnam-si, Gyeonggi-do, South Korea
View Trial DetailsNCT07737067
Arthrosclerosis, Dyslipidemias
Lahore, Punjab Province, Pakistan
View Trial Details